USPatent applicationPatented

Process for amorphous form of donepezil hydrochloride

Granted 10 Aug 2010 · 5 office actions

Life of the application

16 dated events
⤢ drag to zoom20042006200820102012201420162018202020222024ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

The present invention provides a novel process for the preparation of amorphous form of donepezil hydrochloride.

Description

8 parts
›FIELD OF THE INVENTION

The present invention provides a novel process for the preparation of amorphous form of donepezil hydrochloride.

›BACKGROUND OF THE INVENTION

Donepezil hydrochloride of formula (1):

or 2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride is useful for prevention and treatment of alzheimer disease. The therapeutic uses of donepezil hydrochloride and related compounds are disclosed in EP 296560. Amorphous form of donepezil hydrochloride is mentioned in U.S. Pat. No. 6,140,321.

We have discovered a simple novel process for the preparation of amorphous form of donepezil hydrochloride.

The object of the present invention is to provide a novel process for the preparation of the amorphous form of donepezil hydrochloride.

›DETAILED DESCRIPTION OF THE INVENTION

The amorphous donepezil hydrochloride is characterized by having broad x-ray diffraction spectrum as in FIG. 1 .

One aspect of the present invention provides a process for the preparation of amorphous donepezil hydrochloride. Amorphous donepezil hydrochloride is prepared by dissolving donepezil hydrochloride in a mixture comprising an alcoholic solvent and a chlorinated solvent; and removing the solvents from the solution. The solvents can be removed by techniques such as vacuum drying, lyophilization, distillation under vacuum, freeze drying, spray drying, etc. The alcoholic solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, tert-butyl alcohol and n-butyl alcohol. Methanol is a preferred solvent. The suitable chlorinated solvents are chloroform, methylene dichloride, carbontetrachloride and ethylene dichloride. Methylene dichloride and chloroform are preferred solvents.

›BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is a x-ray powder diffraction spectrum of amorphous donepezil hydrochloride.

x-Ray powder diffraction spectrum was measured on a Siemens D5000 x-ray powder diffractometer having a copper-Kα radiation.

The following examples further illustrate the invention.

›Examples4
›EXAMPLE 1

Donepezil hydrochloride (10 gm, obtained by the process described in example 4 of EP 296560) is dissolved in the mixture of methanol (50 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 40° C. for 10 hours to give 9.1 gm of amorphous donepezil hydrochloride.

›EXAMPLE 2

Example 1 is repeated by subjecting the solution to spray drying instead of vacuum drying using nitrogen gas to give amorphous donepezil hydrochloride.

›EXAMPLE 3

Crystalline donepezil hydrochloride (10 gm) is dissolved in the mixure of ethanol (60 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 45° C. for 9 hours to give 9.2 gm of amorphous donepezil hydrochloride.

›EXAMPLE 4

Example 3 is repeated by subjecting the solution to spray drying using nitrogen gas instead of vacuum drying to give amorphous donepezil hydrochloride.

Claims as granted

7 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

3 codes
IPC · International Patent Classification
Section C — Chemistry; metallurgy
  • C07D211/32
USPC · US Patent Classification
546/205546/206

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom20032004200520062007200820092010USPTOApplicantNon-final rejectionNotice of appeal filedResponse after non-finalResponse after non-finalRequest for continued examination
USPTOApplicanthover for detail · click to open
Pendency
7.4 y
2,687 days filing → grant
Office actions
5
non-final + final
Responses
4
1 RCE
Interviews
1
examiner interview summaries
Examiner
Celia Chang
art unit 1625 · TC 1600
Citations: 15 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom2006200820102012201420162018202020222024Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock